Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
- PMID: 27304597
- DOI: 10.1001/jama.2016.5989
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Erratum in
-
Incorrect Test Name.JAMA. 2016 Aug 2;316(5):545. doi: 10.1001/jama.2016.9943. JAMA. 2016. PMID: 27483080 No abstract available.
-
Incorrect Data in Abstract, Text, and Figure.JAMA. 2017 Jun 6;317(21):2239. doi: 10.1001/jama.2017.5918. JAMA. 2017. PMID: 28586871 No abstract available.
Abstract
Importance: Colorectal cancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134,000 persons will be diagnosed with the disease, and about 49,000 will die from it. Colorectal cancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectal cancer is 68 years.
Objective: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer.
Evidence review: The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality; the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps, advanced adenomas based on size, or both, as well as colorectal cancer. The USPSTF also commissioned a comparative modeling study to provide information on optimal starting and stopping ages and screening intervals across the different available screening methods.
Findings: The USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit. Multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. Screening for colorectal cancer is a substantially underused preventive health strategy in the United States.
Conclusions and recommendations: The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history (C recommendation).
Comment in
-
Colorectal Cancer Screening.JAMA. 2016 Oct 25;316(16):1715. doi: 10.1001/jama.2016.13849. JAMA. 2016. PMID: 27784086 No abstract available.
-
Colorectal Cancer Screening Recommendations.JAMA. 2016 Oct 25;316(16):1716. doi: 10.1001/jama.2016.14915. JAMA. 2016. PMID: 27784087 No abstract available.
-
Colorectal Cancer Screening Recommendations.JAMA. 2016 Oct 25;316(16):1715-1716. doi: 10.1001/jama.2016.14918. JAMA. 2016. PMID: 27784088 No abstract available.
Summary for patients in
-
JAMA PATIENT PAGE. Screening for Colorectal Cancer.JAMA. 2016 Jun 21;315(23):2635. doi: 10.1001/jama.2016.7569. JAMA. 2016. PMID: 27305107 No abstract available.
Similar articles
-
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238. JAMA. 2021. PMID: 34003218
-
Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828. JAMA. 2016. PMID: 27305518 Free PMC article.
-
Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2016 Jun 21;315(23):2576-94. doi: 10.1001/jama.2016.3332. JAMA. 2016. PMID: 27305422 Review.
-
Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jun. Report No.: 14-05203-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jun. Report No.: 14-05203-EF-1. PMID: 27441328 Free Books & Documents. Review.
-
Screening for Colorectal Cancer: An Updated Systematic Review [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. Report No.: 08-05-05124-EF-1. PMID: 20722162 Free Books & Documents. Review.
Cited by
-
LncRNA MALAT1 as diagnostic and prognostic biomarker in colorectal cancers: A systematic review and meta-analysis.PLoS One. 2024 Oct 29;19(10):e0308009. doi: 10.1371/journal.pone.0308009. eCollection 2024. PLoS One. 2024. PMID: 39471147 Free PMC article.
-
Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.OTO Open. 2024 Oct 26;8(4):e70040. doi: 10.1002/oto2.70040. eCollection 2024 Oct-Dec. OTO Open. 2024. PMID: 39463807 Free PMC article.
-
USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years.JAMA Netw Open. 2024 Oct 1;7(10):e2436358. doi: 10.1001/jamanetworkopen.2024.36358. JAMA Netw Open. 2024. PMID: 39361285 Free PMC article.
-
Leveraging Multi-Sectoral Partnership for Colorectal Cancer Education and Screening in the African American Community: A Protocol and Preliminary Results.J Cancer Educ. 2024 Sep 23. doi: 10.1007/s13187-024-02506-w. Online ahead of print. J Cancer Educ. 2024. PMID: 39313626
-
Evaluation of long-term benefits and cost-effectiveness of nation-wide colorectal cancer screening strategies in China in 2020-2060: a modelling analysis.Lancet Reg Health West Pac. 2024 Aug 19;51:101172. doi: 10.1016/j.lanwpc.2024.101172. eCollection 2024 Oct. Lancet Reg Health West Pac. 2024. PMID: 39247209 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
